division of infectious diseases Archives
Dec. 21, 2020—Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
Oct. 14, 2020—A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).
Jun. 26, 2020—American Airlines has created a new Travel Health Advisory Panel that includes Vanderbilt University Medical Center infectious disease experts to advise on health and cleaning matters as travelers return over the summer.
May. 27, 2020—Out of concern for fetal safety, pregnant people have typically been excluded from drug trials. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive.
Jan. 9, 2020—The Division of Infectious Diseases at Vanderbilt University Medical Center is seeking applicants for its new Transplant and Immunocompromised Host Infectious Diseases Fellowship Program.
Dec. 16, 2019—The Division of Infectious Diseases is seeking applicants for its new Transplant Infectious Diseases/Immunocompromised Host (TID/ICH) Fellowship Program.
Jul. 18, 2019—A 19-year-old student is leading a multi-institutional collaboration to identify drugs that can be prescribed safely to pregnant women without harming the fetus.
Jul. 11, 2019—Researchers at Vanderbilt University and the University of Michigan in Ann Arbor have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori (H. pylori) to inject a cancer-causing protein into the stomach lining.